Advertisement

The Role of Active Oxygen and the Metabolism of Arachidonic Acid in the Formation of Clastogenic Factor by Human Monocytes

  • Walter Kozumbo
  • Dominique Muehlematter
  • Takafumi Ochi
  • Peter Cerutti

Abstract

The mouse skin tumor promoter phorbol-12-myristate-13-acetate (PMA) is a potent inflammatory agent that not only elicits the infiltration of neutrophils, monocytes and lymphocytes to the site of application (1) but also induces human neutrophils and monocytes, but not lymphocytes, to release clastogenic factor(s) (CF) (2). CF are characterized as lipophilic (ethylacetate extractable) substances of relatively low molecular weight (<10 kDa) whose formation is mediated by superoxide anions and whose activity is inhibited by Cn superoxide dismutase (SOD), free-radical scavengers and antagonists of arachidonic acid (AA) metabolism (3). A correlation between CF formation and lipid peroxidation has been demonstrated (4). These properties of CF are suggestive of free-radical chain reactions which can give rise to lipid peroxides and possibly account for the formation and/or action of CF.

Keywords

Arachidonic Acid Human Monocyte Arachidonic Acid Metabolite Mouse Embryo Fibroblast Free Arachidonic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. Viaje, T. Slaga, M. Wigler and I. Weinstein, Effect of anti-inflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation and production of plasminogen activator. Cancer Res. 37, 1530–1536 (1977).PubMedGoogle Scholar
  2. 2.
    I. Emerit and P. Cerutti, Clastogenic action of tumor promoter phorbol-12-myristate-13-acetate in mixed human leukocyte cultures. Carcinogenesis 4, 1313–1316 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    I. Emerit and P. Cerutti, Tumor promoter phorbol-12-myristate-13-ace-tate induces a clastogenic factor in human lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 79, 7509–7513 (1982).PubMedCrossRefGoogle Scholar
  4. 4.
    I. Emerit, S. Khan and P. Cerutti, Treatment of lymphocyte cultures with a hypoxanthine-xanthine oxidase system induces the formation of transferable clastogenic material. J. Free Radical Biol. Med. 1, 51–57 (1985).CrossRefGoogle Scholar
  5. 5.
    P. Cerutti, Prooxidant states and tumor promotion. Science 22, 375–381 (1985).CrossRefGoogle Scholar
  6. 6.
    I. Emerit, A. Levy and P. Cerutti, Suppression of tumor promoter phorbol myristate acetate-induced chromosome breakage by antioxidants and inhibitors of arachidonic acid metabolism. Mutat. Res. 110, 327–335 (1983).PubMedCrossRefGoogle Scholar
  7. 7.
    Y. Keisari, I. Geva, E. Flescher, H. Golden and G. Lavie, Stimulation of human monocyte oxidative burst and related cytotoxicity by tumor-promoting and non-tumor-promoting diterpene esters, indole alkaloids and poly-acetate-type agents. Int. J. Cancer 36, 467–472 (1985).PubMedCrossRefGoogle Scholar
  8. 8.
    F. Chilton, J. Ellis, S. Olson and R. Wykle, 1-O-alkyl-2-arachidonyl-sn-glycerol-3-phosphocholine. J.Biol. Chem. 259, 12014–12019 (1984).PubMedGoogle Scholar
  9. 9.
    T. Eling, B. Tainer, A. Ally and R. Warnock, Separation of archidonic acid metabolites by high pressure liquid chromatography. Methods Enzymol. 86, 511–517 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    A. Benedetti, R. Fulceri and M. Comporti, Inhibition of calcium sequestration activity of liver microsomes by 4-hydroxyalkenals originating from the peroxidation of liver microsomal lipids. Biochim. Biophys. Acta- 793, 793, 489–493 (1984).PubMedGoogle Scholar
  11. 11.
    G. Camussi, M. Aglietta, R. Coda, F. Bussolino, W. Piacibello and C. Tetta, Release of platelet-activating factor (PAF) and histamine. Immunology 42, 191–199 (1982).Google Scholar
  12. 12.
    T. Yasaka, L. Boxer and R. Baehner, Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). J. Immunol. 128, 1939–1944 (1982).PubMedGoogle Scholar
  13. 13.
    F. Chilton, J. O’Flaherty, C. Walsh, M. Thomas, R. Wykler, L. de Chatelet and B. Waite, Platelet-activating factor. J. Biol. Chem. 257, 5402–5407 (1982).PubMedGoogle Scholar
  14. 14.
    W. Kozumbo, D. Muehlematter, A. Jorg, I. Emerit and P. Cerutti, Phorbol ester-induced formation of clastogenic factor from human monocytes. Carcinogenesis 8, 521–526 (1987).PubMedCrossRefGoogle Scholar
  15. 15.
    T. Ochi and P. Cerutti, Clastogenic action of hydroperoxy-5,8,11,13-icosatetraenoic acids on the mouse embryo fibroblasts C3H/10T2. Proc. Natl. Acad. Sci. U.S.A. 84, 990–994 (1987).PubMedCrossRefGoogle Scholar
  16. 16.
    J. Lewis, T. Hamilton and D. Adams, The effect of macrophage development on the release of reactive oxygen intermediates and lipid oxidation products, and their ability to induce oxidative DNA damage in mammalian cells. Carcinogenesis 7, 813–818 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    S. Lesko, R. Lorentzen and P. Ts’o, Role of superoxide in deoxyribonucleic acid strand scission. Biochemistry 19, 3023–3028 (1980).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Walter Kozumbo
    • 1
  • Dominique Muehlematter
    • 1
    • 2
  • Takafumi Ochi
    • 1
    • 2
  • Peter Cerutti
    • 1
    • 2
  1. 1.Center for Environmental MedicineUniversity of North CarolinaChapel HillUSA
  2. 2.Department of CarcinogenesisSwiss Institute for Experimental Cancer ResearchEpalinges/LausanneSwitzerland

Personalised recommendations